Document Type: Research article
Pharmacological Research Center of Medicinal Plants, Dept. of Pharmacology, School of Medicine, Mashhad University of Medical Sciences, Mashhad
Department of Pharmacology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Doxorubicin (DOX) isan effective anticancer drug. But its clinical application is limited, because DOX induces apoptosis in cardiomyocytes and leads to permanent degenerative cardiomyopathy and heart failure. Recent trainings showed that Hibiscus sabdariffa exhibit pharmacological actions such as potent antioxidant. So, in this study we explored the protective effect of extract of H. sabdariffa against doxorubicin-induced cytotoxicity in H9c2 cells.Cell viability was quantified by MTT assay. Apoptotic cells were determined using PI staining of DNA fragmentation by flowcytometry (sub-G1 peak). Cells were cultured with 5 μM DOX for 24 hr to create the cell damage. H9c2 cells were pretreated with different concentrations (7.81-500 μg/ml) of H. sabdariffa extract (HSE) for 2 hr before DOX treatment in all trials. Pretreatment with HSE increased cell viability at concentration of 31.25-500 μg/ml. Compared to control cells apoptosis was induced in DOX treated cells after 24 hr, (𝑃< 0.001). Pretreatment with HSE significantly decreased cell apoptosis after 24 hr at concentration of 31.25-250 μg/ml.
Our results show that H. sabdariffa could exert the cardioprotective effects against DOX-induced toxicity partly by antiapoptotic activity.